@drmitull.bsky.social
Maximum hepatology. Minimum distractions. General Medicine pro max.
Reposted
DECEMBER ISSUE | REVIEW "Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease"
www.nature.com/articles/s41...
#Liversky
www.nature.com/articles/s41...
#Liversky
November 25, 2025 at 9:01 AM
DECEMBER ISSUE | REVIEW "Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease"
www.nature.com/articles/s41...
#Liversky
www.nature.com/articles/s41...
#Liversky
Reposted
🆕CPG in press❕
EASL Clinical Practice Guidelines on vascular diseases of the liver
Find it here👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)02406-7/fulltext
#LiverSky
@easlnews.bsky.social
EASL Clinical Practice Guidelines on vascular diseases of the liver
Find it here👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)02406-7/fulltext
#LiverSky
@easlnews.bsky.social
November 13, 2025 at 4:07 PM
🆕CPG in press❕
EASL Clinical Practice Guidelines on vascular diseases of the liver
Find it here👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)02406-7/fulltext
#LiverSky
@easlnews.bsky.social
EASL Clinical Practice Guidelines on vascular diseases of the liver
Find it here👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)02406-7/fulltext
#LiverSky
@easlnews.bsky.social
Reposted
November 8, 2025 at 11:02 AM
Reposted
🚨Not every elevation of Creatinine in a corrhotic patient is #HRS!
When faced with AKI in cirrhosis, assess your patient as a whole. This ABCD framework is very helpful
And here are the updated definitions as well!
#TLM25 #LiverSky @aasldnews.bsky.social
When faced with AKI in cirrhosis, assess your patient as a whole. This ABCD framework is very helpful
And here are the updated definitions as well!
#TLM25 #LiverSky @aasldnews.bsky.social
November 8, 2025 at 11:03 AM
🚨Not every elevation of Creatinine in a corrhotic patient is #HRS!
When faced with AKI in cirrhosis, assess your patient as a whole. This ABCD framework is very helpful
And here are the updated definitions as well!
#TLM25 #LiverSky @aasldnews.bsky.social
When faced with AKI in cirrhosis, assess your patient as a whole. This ABCD framework is very helpful
And here are the updated definitions as well!
#TLM25 #LiverSky @aasldnews.bsky.social
Reposted
UC Riverside identified a PTPN2 gene mutation in up to 20% of #IBD patients that disrupts iron absorption, explaining persistent #anemia despite oral supplements. This insight could shift treatment toward IV iron for better outcomes and highlights genetics’ role in IBD complications.
Genetic Mutation Linking Crohn’s Disease to Iron Deficiency Identified
Patients carrying a loss-of-function mutation in the PTPN2 gene show a significant reduction of blood proteins that regulate iron levels.
www.insideprecisionmedicine.com
June 19, 2025 at 1:34 PM
UC Riverside identified a PTPN2 gene mutation in up to 20% of #IBD patients that disrupts iron absorption, explaining persistent #anemia despite oral supplements. This insight could shift treatment toward IV iron for better outcomes and highlights genetics’ role in IBD complications.
Reposted
In the #RedJournal:
Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial
Mishra & Shasthry, et al.
📕 bit.ly/43onq7X
Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial
Mishra & Shasthry, et al.
📕 bit.ly/43onq7X
May 30, 2025 at 8:00 PM
In the #RedJournal:
Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial
Mishra & Shasthry, et al.
📕 bit.ly/43onq7X
Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial
Mishra & Shasthry, et al.
📕 bit.ly/43onq7X
Reposted
🎓 Jean-Pierre Benhamou Clinical State-of-the-Art
🗣️ @docberza.bsky.social on The promise & pitfalls of non-invasive testing – #EASL2025
🧪 NITs: from fibrosis staging ➡️ to prognosis
📈 Last LSM value matters
🔬 OMICS + evolving algorithms = the future
⏳ Baveno VIII will guide next steps
🗣️ @docberza.bsky.social on The promise & pitfalls of non-invasive testing – #EASL2025
🧪 NITs: from fibrosis staging ➡️ to prognosis
📈 Last LSM value matters
🔬 OMICS + evolving algorithms = the future
⏳ Baveno VIII will guide next steps
May 9, 2025 at 3:18 PM
🎓 Jean-Pierre Benhamou Clinical State-of-the-Art
🗣️ @docberza.bsky.social on The promise & pitfalls of non-invasive testing – #EASL2025
🧪 NITs: from fibrosis staging ➡️ to prognosis
📈 Last LSM value matters
🔬 OMICS + evolving algorithms = the future
⏳ Baveno VIII will guide next steps
🗣️ @docberza.bsky.social on The promise & pitfalls of non-invasive testing – #EASL2025
🧪 NITs: from fibrosis staging ➡️ to prognosis
📈 Last LSM value matters
🔬 OMICS + evolving algorithms = the future
⏳ Baveno VIII will guide next steps
Reposted
Do we need to treat cirrhotic PVT, and how? – #EASL2025
🗣️ @jcgarciapagan
📍 LT candidate → anticoagulate if >25%
🚫 No LT → consider if >50%
🔍 Anticoagulation may help beyond recanalization
🛠️ Radiological Rx: for LT candidates not responding or with refractory CSPH
🗣️ @jcgarciapagan
📍 LT candidate → anticoagulate if >25%
🚫 No LT → consider if >50%
🔍 Anticoagulation may help beyond recanalization
🛠️ Radiological Rx: for LT candidates not responding or with refractory CSPH
May 9, 2025 at 3:35 PM
Do we need to treat cirrhotic PVT, and how? – #EASL2025
🗣️ @jcgarciapagan
📍 LT candidate → anticoagulate if >25%
🚫 No LT → consider if >50%
🔍 Anticoagulation may help beyond recanalization
🛠️ Radiological Rx: for LT candidates not responding or with refractory CSPH
🗣️ @jcgarciapagan
📍 LT candidate → anticoagulate if >25%
🚫 No LT → consider if >50%
🔍 Anticoagulation may help beyond recanalization
🛠️ Radiological Rx: for LT candidates not responding or with refractory CSPH
Reposted
🩸 Haemostatic management during procedures in cirrhosis
🗣️ N. Intagliata – #EASL2025
✅ Bleeding is rare, but serious
🚫 Standard tests ≠ bleeding risk
📌 Consider procedure risk, cirrhosis stage & BMI
📋 Have a bleeding plan
🧪 Viscoelastic tests: promising future tool
🗣️ N. Intagliata – #EASL2025
✅ Bleeding is rare, but serious
🚫 Standard tests ≠ bleeding risk
📌 Consider procedure risk, cirrhosis stage & BMI
📋 Have a bleeding plan
🧪 Viscoelastic tests: promising future tool
May 9, 2025 at 3:44 PM
🩸 Haemostatic management during procedures in cirrhosis
🗣️ N. Intagliata – #EASL2025
✅ Bleeding is rare, but serious
🚫 Standard tests ≠ bleeding risk
📌 Consider procedure risk, cirrhosis stage & BMI
📋 Have a bleeding plan
🧪 Viscoelastic tests: promising future tool
🗣️ N. Intagliata – #EASL2025
✅ Bleeding is rare, but serious
🚫 Standard tests ≠ bleeding risk
📌 Consider procedure risk, cirrhosis stage & BMI
📋 Have a bleeding plan
🧪 Viscoelastic tests: promising future tool
Reposted
🩸 Managing acute bleeding in cirrhosis
🗣️ Lara Roberts (London) – #EASL2025
✅ Restrictive transfusion
🚫 No FFP, no tranexamic acid
❓ Platelets & fibrinogen: no clear evidence
🔮 Future: viscoelastic tests to guide therapy?
🗣️ Lara Roberts (London) – #EASL2025
✅ Restrictive transfusion
🚫 No FFP, no tranexamic acid
❓ Platelets & fibrinogen: no clear evidence
🔮 Future: viscoelastic tests to guide therapy?
May 9, 2025 at 3:55 PM
🩸 Managing acute bleeding in cirrhosis
🗣️ Lara Roberts (London) – #EASL2025
✅ Restrictive transfusion
🚫 No FFP, no tranexamic acid
❓ Platelets & fibrinogen: no clear evidence
🔮 Future: viscoelastic tests to guide therapy?
🗣️ Lara Roberts (London) – #EASL2025
✅ Restrictive transfusion
🚫 No FFP, no tranexamic acid
❓ Platelets & fibrinogen: no clear evidence
🔮 Future: viscoelastic tests to guide therapy?
Reposted
💊 DOACs in cirrhosis
🗣️ Cindy Pereira Portela (Lausanne) – #EASL2025
✅ Child A/B: ok (⚠️ no rivaroxaban in B)
🚫 Child C: not recommended
⭐ Apixaban might be the winner — but more data needed
🧩 Case-by-case decision
🤝 Multidisciplinary approach is essential
🗣️ Cindy Pereira Portela (Lausanne) – #EASL2025
✅ Child A/B: ok (⚠️ no rivaroxaban in B)
🚫 Child C: not recommended
⭐ Apixaban might be the winner — but more data needed
🧩 Case-by-case decision
🤝 Multidisciplinary approach is essential
May 9, 2025 at 4:05 PM
💊 DOACs in cirrhosis
🗣️ Cindy Pereira Portela (Lausanne) – #EASL2025
✅ Child A/B: ok (⚠️ no rivaroxaban in B)
🚫 Child C: not recommended
⭐ Apixaban might be the winner — but more data needed
🧩 Case-by-case decision
🤝 Multidisciplinary approach is essential
🗣️ Cindy Pereira Portela (Lausanne) – #EASL2025
✅ Child A/B: ok (⚠️ no rivaroxaban in B)
🚫 Child C: not recommended
⭐ Apixaban might be the winner — but more data needed
🧩 Case-by-case decision
🤝 Multidisciplinary approach is essential
Reposted
The session wraps up with Naim Alkhouri presenting results from the NAVIGATE trial of 2mg/kg, 4mg/kg belapectin or pbo in MASH cirrhosis with portal hypertension (n=~120 per arm) #EASLCirrhosis
May 10, 2025 at 12:30 PM
Reposted
Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
May 9, 2025 at 3:11 PM
Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
Reposted
mRNA-1083 shows superior immune response against influenza and COVID-19 in adults 50 and older, with acceptable safety.
by Rudman Spergel AK, Wu I (...) Shaw CA et 16 al. in JAMA #MedSky
👉 get more here
📖 read the article:
by Rudman Spergel AK, Wu I (...) Shaw CA et 16 al. in JAMA #MedSky
👉 get more here
📖 read the article:
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine
This study examines the immunogenicity and safety of an investigational mRNA-based vaccine against seasonal influenza and SARS-CoV-2 in adults 50 years and older.
jamanetwork.com
May 16, 2025 at 6:40 PM
Reposted
First first author article for Eemeli Puhakka published!
We identified a profile of metabolites separating those with early stage progressive alcohol-related liver disease from non-progressive alcohol-related liver disease using metabolomics
doi.org/10.1111/liv....
#metabolomics #alcohol
We identified a profile of metabolites separating those with early stage progressive alcohol-related liver disease from non-progressive alcohol-related liver disease using metabolomics
doi.org/10.1111/liv....
#metabolomics #alcohol
Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study
Background and Aims Alcohol-related liver disease (ALD) is a major cause of mortality and disability-adjusted life years. It is not fully understood why a small proportion of patients develop progre...
doi.org
May 14, 2025 at 7:10 PM
First first author article for Eemeli Puhakka published!
We identified a profile of metabolites separating those with early stage progressive alcohol-related liver disease from non-progressive alcohol-related liver disease using metabolomics
doi.org/10.1111/liv....
#metabolomics #alcohol
We identified a profile of metabolites separating those with early stage progressive alcohol-related liver disease from non-progressive alcohol-related liver disease using metabolomics
doi.org/10.1111/liv....
#metabolomics #alcohol
Reposted
Acute Kidney Injury in Patients with Cirrhosis
"The authors review the pathophysiology, revised diagnostic definitions, and management of acute kidney injury, a common condition in patients with cirrhosis."
www.nejm.org/doi/full/10....
"The authors review the pathophysiology, revised diagnostic definitions, and management of acute kidney injury, a common condition in patients with cirrhosis."
www.nejm.org/doi/full/10....
May 14, 2025 at 10:20 AM
Acute Kidney Injury in Patients with Cirrhosis
"The authors review the pathophysiology, revised diagnostic definitions, and management of acute kidney injury, a common condition in patients with cirrhosis."
www.nejm.org/doi/full/10....
"The authors review the pathophysiology, revised diagnostic definitions, and management of acute kidney injury, a common condition in patients with cirrhosis."
www.nejm.org/doi/full/10....
Reposted
How often do u get asked to “clear” patients w/cirrhosis for surgery?
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
May 13, 2025 at 1:59 PM
How often do u get asked to “clear” patients w/cirrhosis for surgery?
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
Reposted
What’s new on Hep B treatment guidelines?
#liversky
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
www.journal-of-hepatology.eu/article/S016...
@jhepatology.bsky.social
#liversky
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
www.journal-of-hepatology.eu/article/S016...
@jhepatology.bsky.social
May 13, 2025 at 2:02 PM
What’s new on Hep B treatment guidelines?
#liversky
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
www.journal-of-hepatology.eu/article/S016...
@jhepatology.bsky.social
#liversky
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
www.journal-of-hepatology.eu/article/S016...
@jhepatology.bsky.social
Reposted
Great summary of advances in LRT and systemic treatments for HCC
#liversky
www.gastrojournal.org/article/S001...
@amergastroassn.bsky.social
#liversky
www.gastrojournal.org/article/S001...
@amergastroassn.bsky.social
May 13, 2025 at 2:30 PM
Great summary of advances in LRT and systemic treatments for HCC
#liversky
www.gastrojournal.org/article/S001...
@amergastroassn.bsky.social
#liversky
www.gastrojournal.org/article/S001...
@amergastroassn.bsky.social
Reposted
A practical review of new AGA guidance on PVT management by @drjessicadavis.bsky.social
#liversky
📍don’t delay AC
📍can hold AC for EGD for 48 hours
📍AC does NOT increase risk of bleeding from varices while you wait for EGD
#liversky
📍don’t delay AC
📍can hold AC for EGD for 48 hours
📍AC does NOT increase risk of bleeding from varices while you wait for EGD
April 5, 2025 at 2:00 PM
A practical review of new AGA guidance on PVT management by @drjessicadavis.bsky.social
#liversky
📍don’t delay AC
📍can hold AC for EGD for 48 hours
📍AC does NOT increase risk of bleeding from varices while you wait for EGD
#liversky
📍don’t delay AC
📍can hold AC for EGD for 48 hours
📍AC does NOT increase risk of bleeding from varices while you wait for EGD
Reposted
Treating itch in liver disease
A review from 2017 t.co/NTrAg73AP1
What has changed?
New PPARs and IBAT but access will be limited
#liversky
A review from 2017 t.co/NTrAg73AP1
What has changed?
New PPARs and IBAT but access will be limited
#liversky
December 30, 2024 at 11:14 PM
Treating itch in liver disease
A review from 2017 t.co/NTrAg73AP1
What has changed?
New PPARs and IBAT but access will be limited
#liversky
A review from 2017 t.co/NTrAg73AP1
What has changed?
New PPARs and IBAT but access will be limited
#liversky
Reposted
January 2, 2025 at 1:57 AM
Reposted
Leveraging old hepatitis C therapies
via @nejm.org
www.nejm.org/doi/full/10....
#LiverSky #HepSky #IDSky
via @nejm.org
www.nejm.org/doi/full/10....
#LiverSky #HepSky #IDSky
Leveraging Old Hepatitis C Therapies | NEJM
Older drugs could potentially advance U.S. hepatitis C elimination efforts. The government could act like a business and use all current and historical market information to its advantage.
www.nejm.org
January 2, 2025 at 7:19 AM
Leveraging old hepatitis C therapies
via @nejm.org
www.nejm.org/doi/full/10....
#LiverSky #HepSky #IDSky
via @nejm.org
www.nejm.org/doi/full/10....
#LiverSky #HepSky #IDSky
Reposted
Updated HCC management guidelines by @easlnews.bsky.social
Must read 👇🏼👇🏼👇🏼
www.journal-of-hepatology.eu/article/S016...
#Liversky
Must read 👇🏼👇🏼👇🏼
www.journal-of-hepatology.eu/article/S016...
#Liversky
December 17, 2024 at 12:48 PM
Updated HCC management guidelines by @easlnews.bsky.social
Must read 👇🏼👇🏼👇🏼
www.journal-of-hepatology.eu/article/S016...
#Liversky
Must read 👇🏼👇🏼👇🏼
www.journal-of-hepatology.eu/article/S016...
#Liversky
Reposted
Next, Elizabeth Powell charts the momentous changes in #MASLD research and treatment in 2024, from first drug approval to updated guidelines and new biomarkers
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
A new treatment and updated clinical practice guidelines for MASLD - Nature Reviews Gastroenterology & Hepatology
The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatoh...
www.nature.com
November 20, 2024 at 9:15 AM
Next, Elizabeth Powell charts the momentous changes in #MASLD research and treatment in 2024, from first drug approval to updated guidelines and new biomarkers
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky